Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
This is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.
创建时间：
2019-07-15
